Xiaoyan Du
About Xiaoyan Du
Xiaoyan Du is the Associate Director at Bristol Myers Squibb in Redwood City, California, with extensive experience in bioanalytical and biomarker strategies for biologics drug development.
Company: Bristol Myers Squibb
Xiaoyan Du currently holds the position of Associate Director at Bristol Myers Squibb in Redwood City, California. Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. Her role there encompasses significant contributions to developing bioanalytical and biomarker strategies for biologics drug development, leveraging her extensive background and expertise in the field.
Career at Pionyr Immunotherapeutics
Xiaoyan Du worked at Pionyr Immunotherapeutics from 2018 to 2021 as Associate Director, focusing on Biomarkers, Bioanalysis, and Immunogenicity, and from 2018 to 2020 as Principal Scientist in Preclinical and Translational Sciences. In these roles, she specialized in assay development and validation for clinical biomarkers. Her contributions included significant efforts in protein, antibody, and hybridoma screening and characterization.
Professional Experience at Merck
From 2012 to 2018, Xiaoyan Du served as an Associate Principal Scientist at Merck in Palo Alto, California. During her six-year tenure, she gained substantial expertise in evaluating biologics for cytokine release syndrome risk and developing bioanalytical strategies for biologics drug development. Her work included proof-of-concept (POC) studies and in vitro diagnostics (IVD) across various disease areas, demonstrating her broad scientific proficiency.
Education: Universität Bern
Xiaoyan Du completed her PhD in Biochemistry at Universität Bern, culminating in a Doctor of Philosophy degree from 1999 to 2002. During her doctoral studies, she developed a robust foundation in biochemical research methodologies, which has significantly contributed to her subsequent professional achievements. This academic background underpins her extensive expertise in developing bioanalytical and biomarker strategies for biologics drug development.